Therapeutic drug monitoring in CML patients on imatinib

被引：30

作者：

Blasdel, Carolyn ^{[1
]}

Egorin, Merrill J. ^{[1
]}

Lagattuta, Theodore F. ^{[1
]}

Druker, Brian J. ^{[1
]}

Deininger, Michael W. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA

来源：

BLOOD | 2007年 / 110卷 / 05期

关键词：

D O I：

10.1182/blood-2007-03-079871

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1699 / 1701

页数：3

共 4 条

[1] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[2]

Larson RA, 2006, BLOOD, V108, p131A

[3] Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients [J].

Peng, B ;

Hayes, M ;

Resta, D ;

Racine-Poon, A ;

Druker, BJ ;

Talpaz, M ;

Sawyers, CL ;

Rosamilia, M ;

Ford, J ;

Lloyd, P ;

Capdeville, R .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :935-942

[4] Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia [J].

Picard, Stephane ;

Titier, Karine ;

Etienne, Gabriel ;

Teilhet, Ernmanuelle ;

Ducint, Dominique ;

Bernard, Marie-Agnes ;

Lassalle, Regis ;

Marit, Gerald ;

Reiffers, Josy ;

Begaud, Bernard ;

Moore, Nicholas ;

Molimard, Mathieu ;

Mahon, Francois-Xavier .

BLOOD, 2007, 109 (08) :3496-3499

← 1 →